Carcinoembryonic antigen (CEA)—the only FDA-approved biomarker in colorectal cancer (CRC)—is the marker of choice for monitoring the response of conventional therapy and detecting disease recurrence (Locker et al, 2006; Duffy et al, 2007). This evidence concerns the gene CEACAM5 and colorectal carcinoma.